eu final clinical trial results released.., page-17

A good but expected result in my opinion.

Of more interest is who's the partner and whats the net royalty rate. I get a 5 year dcf valuation of 374c using a 25% net royalty where earnings build to 320m by 2016. The dcf valuation jumps to 456c if the net royalty rate is 30%. Easy to see how important it is to hold out for a good deal.

Im also hoping Steve will release some earnings targets and market data. If they do we should see some numbers to support minimum earnings targets of 300m by 2015. Which i think will attract some new buyers.

Not long to wait now.